

**SUPPLEMENTAL FIG. S1.** Inhibition of proliferation of thyroid cancer cells by CI-1040 or U0126. Cells (C643, TPC1, BCPAP, SW736, and K1) were grown in RPMI supplemented with 10% FBS (**A**, **B**) or 2% FBS (**C**, **D**) and treated with or without CI-1040 ( $0.5 \mu$ M) (**A**, **C**) or U0126 ( $3 \mu$ M) (**B**, **D**) for 3 and 6 days. Inhibitors and culture media were replenished every 72 hours. Cell proliferation was measured using the MTS assay (Promega), as described in "Materials and Methods". Vehicle/control was set to 100% and is represented by the dashed line. Results presented are the S.D. (**A**, **B**) or S.E.M. (**C**, **D**) from four to eight separate experiments done in quadruplicate. Statistical analysis (two-tailed *t*-test) indicated that at 6 days, the TPC1 and K1 (p = 0.03), and SW1736 cells (p < 0.0001) were significantly inhibited by CI-1040; and the TPC1 and K1 cells (p < 0.05) were significantly inhibited by U0126 treatment when grown in RPMI/10% FBS (**A**, **B**). When grown in RPMI/2% FBS, the growth of the TPC1 and BCPAP (p < 0.02) and SW1736 cells (p < 0.0001) was significantly inhibited by CI-1040; and the growth of the C643 (p = 0.04), TPC1 and BCPAP (p < 0.01), and SW1736 (p < 0.0001) was significantly inhibited by U0126.